OBJECTIVE: We report clinical and functional outcomes obtained after application of an autologous bioengineered composite skin (ABCS) produced in a single Spanish tissue-engineering unit. MATERIALS/ METHODS: Twenty-five burned patients treated with ABCS from 1999 to 2007 in five burn centres were included in the study. Mean age was 29 years (SD 11), with mean total body surface area (TBSA) burned being 74% (SD 17) and mean full-thickness injury of 61% (SD 19) of TBSA. RESULTS: The mean area initially engrafted with ABCS was 24% (SD 13) of TBSA, with a final take of 49% (SD 30, range 0-100%). ABCS achieved permanent coverage of a mean of 11% (SD 8) of TBSA. In subset analyses, lack of pre- and post-application wound bed infection and lack of serious acute systemic complications at the time of engraftment were significantly associated with better ABCS take. CONCLUSIONS: Final take obtained with ABCS could be improved with the use of non-cytotoxic topical antibiotics following engraftment. The use of plasma to prepare ABCS reduces production costs: cost-effectiveness ratio is not a limitation for its use. In terms of patient satisfaction, cosmetic/functional outcomes (general appearance, texture, flexibility, sensitivity and colour) of ABCS and split-thickness autografts are not different statistically.
OBJECTIVE: We report clinical and functional outcomes obtained after application of an autologous bioengineered composite skin (ABCS) produced in a single Spanish tissue-engineering unit. MATERIALS/ METHODS: Twenty-five burned patients treated with ABCS from 1999 to 2007 in five burn centres were included in the study. Mean age was 29 years (SD 11), with mean total body surface area (TBSA) burned being 74% (SD 17) and mean full-thickness injury of 61% (SD 19) of TBSA. RESULTS: The mean area initially engrafted with ABCS was 24% (SD 13) of TBSA, with a final take of 49% (SD 30, range 0-100%). ABCS achieved permanent coverage of a mean of 11% (SD 8) of TBSA. In subset analyses, lack of pre- and post-application wound bed infection and lack of serious acute systemic complications at the time of engraftment were significantly associated with better ABCS take. CONCLUSIONS: Final take obtained with ABCS could be improved with the use of non-cytotoxic topical antibiotics following engraftment. The use of plasma to prepare ABCS reduces production costs: cost-effectiveness ratio is not a limitation for its use. In terms of patient satisfaction, cosmetic/functional outcomes (general appearance, texture, flexibility, sensitivity and colour) of ABCS and split-thickness autografts are not different statistically.
Authors: Maia M Alexaline; Marina Trouillas; Muriel Nivet; Emilie Bourreau; Thomas Leclerc; Patrick Duhamel; Michele T Martin; Christelle Doucet; Nicolas O Fortunel; Jean-Jacques Lataillade Journal: Stem Cells Transl Med Date: 2015-04-06 Impact factor: 6.940
Authors: Andrés Montero; Cristina Quílez; Leticia Valencia; Paula Girón; José Luis Jorcano; Diego Velasco Journal: Int J Mol Sci Date: 2021-06-23 Impact factor: 5.923
Authors: Marija Stojic; Joaquín Ródenas-Rochina; María Luisa López-Donaire; Israel González de Torre; Miguel González Pérez; José Carlos Rodríguez-Cabello; Lucy Vojtová; José Luis Jorcano; Diego Velasco Journal: Polymers (Basel) Date: 2021-06-28 Impact factor: 4.329
Authors: Dahiana Mojena-Medina; Moritz Hubl; Manuel Bäuscher; José Luis Jorcano; Ha-Duong Ngo; Pablo Acedo Journal: Sensors (Basel) Date: 2020-10-08 Impact factor: 3.576